59 related articles for article (PubMed ID: 7577475)
1. Loss of heterozygosity in sporadic breast tumours at the BRCA2 locus on chromosome 13q12-q13.
Cleton-Jansen AM; Collins N; Lakhani SR; Weissenbach J; Devilee P; Cornelisse CJ; Stratton MR
Br J Cancer; 1995 Nov; 72(5):1241-4. PubMed ID: 7577475
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium.
Thompson D; Szabo CI; Mangion J; Oldenburg RA; Odefrey F; Seal S; Barfoot R; Kroeze-Jansema K; Teare D; Rahman N; Renard H; Mann G; Hopper JL; Buys SS; Andrulis IL; Senie R; Daly MB; West D; Ostrander EA; Offit K; Peretz T; Osorio A; Benitez J; Nathanson KL; Sinilnikova OM; Olàh E; Bignon YJ; Ruiz P; Badzioch MD; Vasen HF; Futreal AP; Phelan CM; Narod SA; Lynch HT; Ponder BA; Eeles RA; Meijers-Heijboer H; Stoppa-Lyonnet D; Couch FJ; Eccles DM; Evans DG; Chang-Claude J; Lenoir G; Weber BL; Devilee P; Easton DF; Goldgar DE; Stratton MR;
Proc Natl Acad Sci U S A; 2002 Jan; 99(2):827-31. PubMed ID: 11792833
[TBL] [Abstract][Full Text] [Related]
3. The DNA sequence and analysis of human chromosome 13.
Dunham A; Matthews LH; Burton J; Ashurst JL; Howe KL; Ashcroft KJ; Beare DM; Burford DC; Hunt SE; Griffiths-Jones S; Jones MC; Keenan SJ; Oliver K; Scott CE; Ainscough R; Almeida JP; Ambrose KD; Andrews DT; Ashwell RI; Babbage AK; Bagguley CL; Bailey J; Bannerjee R; Barlow KF; Bates K; Beasley H; Bird CP; Bray-Allen S; Brown AJ; Brown JY; Burrill W; Carder C; Carter NP; Chapman JC; Clamp ME; Clark SY; Clarke G; Clee CM; Clegg SC; Cobley V; Collins JE; Corby N; Coville GJ; Deloukas P; Dhami P; Dunham I; Dunn M; Earthrowl ME; Ellington AG; Faulkner L; Frankish AG; Frankland J; French L; Garner P; Garnett J; Gilbert JG; Gilson CJ; Ghori J; Grafham DV; Gribble SM; Griffiths C; Hall RE; Hammond S; Harley JL; Hart EA; Heath PD; Howden PJ; Huckle EJ; Hunt PJ; Hunt AR; Johnson C; Johnson D; Kay M; Kimberley AM; King A; Laird GK; Langford CJ; Lawlor S; Leongamornlert DA; Lloyd DM; Lloyd C; Loveland JE; Lovell J; Martin S; Mashreghi-Mohammadi M; McLaren SJ; McMurray A; Milne S; Moore MJ; Nickerson T; Palmer SA; Pearce AV; Peck AI; Pelan S; Phillimore B; Porter KM; Rice CM; Searle S; Sehra HK; Shownkeen R; Skuce CD; Smith M; Steward CA; Sycamore N; Tester J; Thomas DW; Tracey A; Tromans A; Tubby B; Wall M; Wallis JM; West AP; Whitehead SL; Willey DL; Wilming L; Wray PW; Wright MW; Young L; Coulson A; Durbin R; Hubbard T; Sulston JE; Beck S; Bentley DR; Rogers J; Ross MT
Nature; 2004 Apr; 428(6982):522-8. PubMed ID: 15057823
[TBL] [Abstract][Full Text] [Related]
4. Significance of
Chakraborty G; Armenia J; Mazzu YZ; Nandakumar S; Stopsack KH; Atiq MO; Komura K; Jehane L; Hirani R; Chadalavada K; Yoshikawa Y; Khan NA; Chen Y; Abida W; Mucci LA; Lee GM; Nanjangud GJ; Kantoff PW
Clin Cancer Res; 2020 Apr; 26(8):2047-2064. PubMed ID: 31796516
[TBL] [Abstract][Full Text] [Related]
5. Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in
Carneiro BA; Collier KA; Nagy RJ; Pamarthy S; Sagar V; Fairclough S; Odegaard J; Lanman RB; Costa R; Taxter T; Kuzel TM; Fan A; Chae YK; Cristofanilli M; Hussain MH; Abdulkadir SA; Giles FJ
JCO Precis Oncol; 2018; 2():. PubMed ID: 31501807
[TBL] [Abstract][Full Text] [Related]
6. Role of the general practitioner in the care of BRCA1 and BRCA2 mutation carriers: General practitioner and patient perspectives.
Vande Perre P; Toledano D; Corsini C; Escriba E; Laporte M; Bertet H; Yauy K; Toledano A; Galibert V; Baudry K; Clotet L; Million E; Picot MC; Geneviève D; Pujol P
Mol Genet Genomic Med; 2018 Nov; 6(6):957-965. PubMed ID: 30308700
[TBL] [Abstract][Full Text] [Related]
7. Post-transcriptional Regulation of BRCA2 through Interactions with miR-19a and miR-19b.
Mogilyansky E; Clark P; Quann K; Zhou H; Londin E; Jing Y; Rigoutsos I
Front Genet; 2016; 7():143. PubMed ID: 27630665
[TBL] [Abstract][Full Text] [Related]
8. Integrating genetics and epigenetics in breast cancer: biological insights, experimental, computational methods and therapeutic potential.
Cava C; Bertoli G; Castiglioni I
BMC Syst Biol; 2015 Sep; 9():62. PubMed ID: 26391647
[TBL] [Abstract][Full Text] [Related]
9. Mutational profiling of familial male breast cancers reveals similarities with luminal A female breast cancer with rare TP53 mutations.
Deb S; Wong SQ; Li J; Do H; Weiss J; Byrne D; Chakrabarti A; Bosma T; ; Fellowes A; Dobrovic A; Fox SB
Br J Cancer; 2014 Dec; 111(12):2351-60. PubMed ID: 25490678
[TBL] [Abstract][Full Text] [Related]
10. ATR inhibition preferentially targets homologous recombination-deficient tumor cells.
Krajewska M; Fehrmann RS; Schoonen PM; Labib S; de Vries EG; Franke L; van Vugt MA
Oncogene; 2015 Jun; 34(26):3474-81. PubMed ID: 25174396
[TBL] [Abstract][Full Text] [Related]
11. Targeting signaling pathways in epithelial ovarian cancer.
Smolle E; Taucher V; Pichler M; Petru E; Lax S; Haybaeck J
Int J Mol Sci; 2013 May; 14(5):9536-55. PubMed ID: 23644885
[TBL] [Abstract][Full Text] [Related]
12. Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance.
Spearman AD; Sweet K; Zhou XP; McLennan J; Couch FJ; Toland AE
J Clin Oncol; 2008 Nov; 26(33):5393-400. PubMed ID: 18824701
[TBL] [Abstract][Full Text] [Related]
13. A novel BRCA2 mutation in an Indonesian family found with a new, rapid, and sensitive mutation detection method based on pooled denaturing gradient gel electrophoresis and targeted sequencing.
Purnomosari D; Paramita DK; Aryandono T; Pals G; van Diest PJ
J Clin Pathol; 2005 May; 58(5):493-9. PubMed ID: 15858120
[TBL] [Abstract][Full Text] [Related]
14. The D13S171 marker, misannotated to BRCA2, links the AS3 gene to various cancers.
Geck P; Sonnenschein C; Soto AM
Am J Hum Genet; 2001 Aug; 69(2):461-3. PubMed ID: 11452363
[No Abstract] [Full Text] [Related]
15. Androgen-induced proliferative quiescence in prostate cancer cells: the role of AS3 as its mediator.
Geck P; Maffini MV; Szelei J; Sonnenschein C; Soto AM
Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10185-90. PubMed ID: 10963680
[TBL] [Abstract][Full Text] [Related]
16. Detection of loss of heterozygosity at RAD51, RAD52, RAD54 and BRCA1 and BRCA2 loci in breast cancer: pathological correlations.
Gonzalez R; Silva JM; Dominguez G; Garcia JM; Martinez G; Vargas J; Provencio M; España P; Bonilla F
Br J Cancer; 1999 Oct; 81(3):503-9. PubMed ID: 10507777
[TBL] [Abstract][Full Text] [Related]
17. BRCA1 and BRCA2 proteins: roles in health and disease.
Duncan JA; Reeves JR; Cooke TG
Mol Pathol; 1998 Oct; 51(5):237-47. PubMed ID: 10193517
[TBL] [Abstract][Full Text] [Related]
18. A population study of mutations and LOH at breast cancer gene loci in tumours from sister pairs: two recurrent mutations seem to account for all BRCA1/BRCA2 linked breast cancer in Iceland.
Arason A; Jonasdottir A; Barkardottir RB; Bergthorsson JT; Teare MD; Easton DF; Egilsson V
J Med Genet; 1998 Jun; 35(6):446-9. PubMed ID: 9643283
[TBL] [Abstract][Full Text] [Related]
19. Exclusion of BBC1 and CMAR as candidate breast tumour-suppressor genes.
Moerland E; Breuning MH; Cornelisse CJ; Cleton-Jansen AM
Br J Cancer; 1997; 76(12):1550-3. PubMed ID: 9413939
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of loss of heterozygosity at BRCA2 in human breast carcinoma.
Bièche I; Noguès C; Rivoilan S; Khodja A; Latil A; Lidereau R
Br J Cancer; 1997; 76(11):1416-8. PubMed ID: 9400936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
